Publications
Detailed Information
DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis
Cited 27 time in
Web of Science
Cited 27 time in Scopus
- Authors
- Issue Date
- 2008-01-29
- Citation
- Exp Biol Med (Maywood). 233(2):180-191
- Keywords
- Acute Disease ; Animals ; Apoptosis/drug effects ; Body Weight/drug effects ; Cell Transformation, Neoplastic ; Colitis/*chemically induced/complications/enzymology/*prevention & control ; Colonic Neoplasms/complications/pathology/*prevention & control ; Cyclooxygenase 2/metabolism ; Dextran Sulfate/*pharmacology ; Disease Models, Animal ; Flavonoids/*pharmacology ; I-kappa B Kinase/metabolism ; Ki-67 Antigen/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Phosphorylation/drug effects
- Abstract
- Previously, we have shown that DA-6034, a synthetic derivative of flavonoid eupatilin, inhibited NF-kappaB activation in colon epithelial cells and prevented trinitrobenzene sulfonic acid-induced rat colitis. The aim of this study was to investigate the preventive and therapeutic effect of DA-6034 on dextran sulfate sodium (DSS)-induced colitis and on inflammation-related cancer. C57BL/6 mice were given 4% DSS for 5 days with and without DA-6034 in the acute preventive model. In the acute therapeutic model, mice were given 4% DSS for 5 days followed by rectal administration of DA-6034. Colitis was quantified by body weight, disease activity index (DAI), colon length, and histology. In the inflammation-related cancer model, mice were given a single intraperitoneal injection of azoxymethane, then three cycles of 2% DSS for 5 days, then 2 weeks of free water consumption. Apoptosis was determined by in situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay, and the expression of Ki-67, phospho-kappaB kinase alpha (IKKalpha), and COX-2 were evaluated by immunohistochemistry. In both the acute preventive and acute therapeutic models, DA-6034 significantly attenuated DSS-induced weight loss, an increase in DAI, and a shortening of colon length. DA-6034-treated mice maintained crypt architecture and revealed a scanty infiltration of inflammatory cells in both the preventive and therapeutic models. In the inflammation-related cancer model, DA-6034 reduced the number of colon tumors and ameliorated weight loss and shortening of colon length. DA-6034 strongly enhanced apoptosis and inhibited the expression of COX-2 and phospho-IKKalpha in inflammation-related colon cancer models. Our results suggest that DA-6034 prevents acute murine colitis and inhibits inflammation-related colon carcinogenesis. DA-6034 could be a potential therapeutic agent for inflammatory bowel disease.
- ISSN
- 1535-3702 (Print)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18222973
http://www.ebmonline.org/cgi/reprint/233/2/180.pdf
https://hdl.handle.net/10371/67866
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.